These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7901961)

  • 1. Plasma bevantolol concentration and heart rate in rabbits.
    Liu XQ; Ye XL; Zhu HQ; Huang SK
    Zhongguo Yao Li Xue Bao; 1993 May; 14(3):200-2. PubMed ID: 7901961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blocking drug metipranolol: plasma levels and pharmacodynamic action in man.
    Mayer O; Cepelák V; Vitous J; Potmĕsil J
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):113-9. PubMed ID: 6103879
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers.
    McNeil JJ; Drummer OH; Anderson AI; Louis WJ
    J Cardiovasc Pharmacol; 1986; 8(6):1201-7. PubMed ID: 2434747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.
    Volz-Zang C; Eckrich B; Jahn P; Schneidrowski B; Schulte B; Palm D
    Eur J Clin Pharmacol; 1994; 46(5):399-404. PubMed ID: 7957532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevantolol disposition in patients with hepatic cirrhosis.
    Nattel S; Lawand S; Matthews C; McCans J
    J Clin Pharmacol; 1987 Dec; 27(12):962-6. PubMed ID: 2893814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol.
    Horinouchi T; Morishima S; Tanaka T; Suzuki F; Tanaka Y; Koike K; Miwa S; Muramatsu I
    Life Sci; 2007 Jul; 81(5):399-404. PubMed ID: 17628611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
    Frishman WH; Goldberg RJ; Benfield P
    Drugs; 1988 Jan; 35(1):1-21. PubMed ID: 2894292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics--observations with beta-adrenoceptor antagonists.
    De Mey C
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):453-7. PubMed ID: 9352395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings: Preliminary observations on the human pharmacology of I.C.I. 66082 in normal volunteers.
    Graham BR; Littlejohns DW; Prichard BN; Scales B; Southorn P
    Br J Pharmacol; 1973 Sep; 49(1):154P-155P. PubMed ID: 4150762
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic parameters of bevantolol in volunteers.
    Vermeij P; van Brummelen P
    Eur J Clin Pharmacol; 1986; 30(3):375-7. PubMed ID: 2874033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog].
    Yin XX; Zhang YD
    Yao Xue Xue Bao; 1997 Jun; 32(6):411-5. PubMed ID: 11596322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat.
    Yin XX; Zhang YD; Luo JP; Huang XP; Shen JP; Ding Y; Huang DK
    Zhongguo Yao Li Xue Bao; 1997 Mar; 18(2):104-8. PubMed ID: 10072957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic studies in man with an antianginal agent 'Visacor'.
    Cockshott ID; McAinsh J; Norris S
    Biopharm Drug Dispos; 1990 Apr; 11(3):253-63. PubMed ID: 1970266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of pharmacological properties of various potential beta adrenolytics of the aryloxypropanolamine type].
    Béderová E; Edelsteinová S; Racanský V; Svec P
    Cesk Farm; 1982 Sep; 31(7):279-85. PubMed ID: 6128077
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical pharmacology of trimepranol (pharmacokinetic informations and effects on heart rate in healthy individuals)].
    Mayer O; Petrlík M; Vitous J; Cepelák V
    Vnitr Lek; 1976 Nov; 22(11):1102-9. PubMed ID: 12612
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.
    Solimon M; Massry SG; Campese VM
    Am J Cardiol; 1986 Nov; 58(12):21E-24E. PubMed ID: 2878596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin.
    Lefebvre RA; Bogaert MG; Duprez D
    Eur J Clin Pharmacol; 1990; 38(5):505-7. PubMed ID: 1974206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
    Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
    Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy.
    Hurst AK; Shotan A; Hoffman K; Johnson J; Goodwin TM; Koda R; Elkayam U
    Pharmacotherapy; 1998; 18(4):840-6. PubMed ID: 9692658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory effect of bevantolol on the accumulation of non-esterified fatty acids during ischaemia in the dog heart in situ.
    Miura I; Nasa Y; Ichihara K; Abiko Y
    Clin Exp Pharmacol Physiol; 1991 Apr; 18(4):259-62. PubMed ID: 1676940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.